[Role of allogeneic hematopoietic cell transplantation after anti-CD19 CAR T-cell treatment: Guidelines from the SFGM-TC]. / Place de l'allogreffe de cellules souches hématopoïétiques après traitement par CAR T-cell anti-CD19 : recommandations de la SFGM-TC.
Bull Cancer
; 110(2S): S108-S115, 2023 Feb.
Article
en Fr
| MEDLINE
| ID: mdl-35791974
ABSTRACT
The role of allogeneic hematopoietic cell transplantation (allo-HCT) after CAR T- treatment cells in hematologic malignancies is currently controversial. Prolonged remissions after several years of follow-up suggest that there is a curative effect of CAR T-cells therapy, whereas allo-HCT was previously considered the only curative treatment in relapse situation. The aim of this harmonization workshop is to detail the existing data in the literature on the feasibility of allo-HCT after CAR T-cells and to propose to consider allograft in selected patients with B-acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). In B-ALL, various intrinsic factors (inherent to the patient, to the disease, to the type of CAR T-cells) and especially various post CAR T-cells criteria (early expansion kinetics, residual disease at D28, early loss of B-cell aplasia) should lead to consider performing allo-HCT before the occurrence of a relapse. In DLBCL, although there are risk factors for relapse at diagnosis and prior to CAR T-cells therapy, response assessed by PET-CT at three months is critical and allo-HCT cannot currently be recommended in cases of complete or partial remission. In any case, if the age is appropriate for allogeneic transplantation, HLA typing should be performed before CAR T-cells treatment in order not to delay the allo-HCT project if needed.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Leucemia-Linfoma Linfoblástico de Células Precursoras B
/
Trasplante de Células Madre Hematopoyéticas
/
Neoplasias Hematológicas
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
Tipo de estudio:
Guideline
/
Risk_factors_studies
Límite:
Humans
Idioma:
Fr
Revista:
Bull Cancer
Año:
2023
Tipo del documento:
Article